Table 4. Comparison of FDA-Approved Dosing Regimens for Various PPIs
| Indication |
|
|
|
|
|
| Symptomatic GERD | 20 mg QD x 4 weeks |
15 mg QD up to 8 weeks |
20 mg QD x 4 weeks* |
||
| Healing erosive esophagitis | 20-40 mg QD x 4-8 weeks |
30 mg QD up to 8 weeks |
20 mg QD x 4-8 weeks |
40 mg QD up to 8 weeks |
20 mg QD x 4-8 weeks |
| Maintenance of erosive esophagitis | 20 mg QD | 15 mg QD | 20 mg QD | 20 mg QD | |
| Hypersecretory
conditions (eg, ZES) |
60 mg QD | 60 mg QD; 80-360 mg/day | 60 mg QD; 100 mg QD-60 mg BID | ||
| Duodenal ulcers | 15 mg QD x 4 weeks |
20 mg QD x 4 weeks* | 20 mg QD up to 4 weeks |
||
| Duodenal ulcers-maintenance | 15 mg QD | ||||
| Gastric ulcers | 30 mg QD up to 8 weeks |
40 mg QD x 4-8 weeks |
|||
| H. pylori eradication | 40 mg QD x 10 days plus antibiotics |
30 mg BID plus antibiotics x 10-14 days; 30 mg TID plus amoxicillin x 14 days |
20 mg BID plus antibiotics x 10 days, followed by 20 mg QD X 18 days; 40 mg QD plus clarithromycin x 14 days, followed by 20 mg QD x 14 days | ||
| Treatment of NSAID-induced gastric ulcers | 30 mg QD x 8 weeks | ||||
| Prevention of NSAID-induced gastric ulcers | 15 mg QD up to 12 weeks |
QD = once daily; BID = twice
daily; TID = three times daily
* = If symptoms do not resolve completely after 4 weeks, an additional 4 weeks
of treatment may be considered.
Click Here to Return to Article